Authors
Latest:
Special DeliveryNew drug delivery mechanisms and devices are an opportunity to build relationship with the ultimate customer: the patient.
Latest:
New Rules for a New AfricaAs growth in the BRICs and other emerging economies begins to stabilize, companies are finally turning their attention to Africa-a hidden trove of potential that is only as good as you make it.
Latest:
Orchestrating ComplianceProduct managers would be less disrupted if compliance activities at pharma companies were more anticipatory than reactionary.
Latest:
Feeling No PainLifecycle management and line extensions helped the Percocet franchise generate steady annual growth, rising from $40 million in 1997 sales to $214 million in 2003, despite the fact that it had no patent protection.
Latest:
Digital Education a Key Bridge to Tapping Emerging MarketsIn our second Q&A installment previewing next month’s iPharma2014 conference in New York City, we spoke with David Stern.
Latest:
A Better Way to BuildJust a few years ago, financiers were celebrating the "recession-proof" US economy, betting on the success of dot-coms and ridiculing the cautious few. Today, pharma industry experts tout mergers and acquisitions as a panacea to solve growth problems, reduce costs, increase sales, and renew R&D productivity.
Latest:
Emerging Biopharma Tackles the Opioid CrisisDr. Steven Fox, CEO of Akelos Inc., discusses the challenges of developing new non-opioid medical products as the need intensifies as the crisis worsens.
Latest:
Pricing Climate Heats Up in US and EuropeIn 2003, Big Pharma produced only a dozen new drugs. At the same time, it came under new pressure to create value from those thin pipelines. In that "hot squeeze" of a climate, pharma companies needed price premiums for every product in every market. They were more successful in some countries than in others. Other pricing trends also took their toll.
Latest:
Analysis of Risk-Based Quality Management Approach - White PaperThis white paper investigates best practices and tangible benefits associated with a risk-based quality management (RBQM) approach to clinical trial management.
Latest:
Halting the HypeUnfortunately, companies sometimes violate the public trust by issuing false or misleading statements about FDA-related issues, such as the progress of FDA's pre-market review. When we identify suspected misstatements, we have a new process to bring them to the attention of the SEC staff as quickly and efficiently as possible." Then FDA Commissioner Mark McClellan issued that statement in a February press release.
Latest:
Case Study: Science-Based SellingThe relaunch team focused on clinical differentiation to drive business with science.
Latest:
Bridging Care Delivery with Clinical ResearchIn this Q&A, Craig Serra, head of commercial solutions and partnerships within the clinical research business unit at Flatiron Health (affiliate of the Roche Group), shares his perspective on clinical research, the role of data, and Flatiron Health’s efforts to that end.
Latest:
Inside DDMAC: A Conversation with Thomas AbramsDespite heightened scrutiny from industry advocates and the beginnings of self-imposed regulation, pharma companies' violations of DTC regulations have been getting worse, says Tom Abrams, director of FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC). Abrams has been on all sides of drug marketing, from receiving promotions as a pharmacist to creating promotions as a member of industry to regulating promotions as the head of DDMAC. As such, he's in good position to see the big picture.
Latest:
Optimal Pricing StrategiesPricing has never been more of a key issue for the industry than it is right now. Yet, even with the increased importance of pricing strategies, a lack of focus on critical market factors leads many manufacturers to forego profits or increase their vulnerability to aggressive payers. Aligning pricing and contracting can achieve a sustainable competitive advantage-if product managers objectively assess a product's clinical benefits and address two key questions:
Latest:
Data Unleashed: Cooperation Among CompetitorsCharting two years of collaborative progress in clinical trial data sharing.
Latest:
Paying for the Future of MedicineThe three leading justifications for sticker-shocking drug prices in the US.
Latest:
A New Game Plan for Pharma HRNew dynamics are forcing the industry's human resource departments to rethink their operational game plans. The drivers-consolidation, globalization, scientific advances, public policy, and competition-have pushed HR leaders into new territory to address business needs.
Latest:
Dangerous Liaisons: Terrorism and PharmaHow vulnerable is Big Pharma to the predations of organized terrorist groups or that rogue malcontent with an agenda to wreak havoc on society?
